EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Cerebral Venous Thrombosis following Sacituzumab Govitecan in Metastatic Breast Cancer: A Case Report

Ahmed M. Abdalhadi, Fadel Alqatati, Asiya Thakur, Ali Ali Alsuyihili, Muhammed Hajmusa, Mohammad Elhissi, Nabil E. Omar

Case Reports in Oncology · 2026-08-25 · 19 (1) · 1542-1550

DOI: 10.1159/cro/abzag033 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Cerebral venous thrombosis (CVT) is an uncommon but potentially serious cerebrovascular disorder that may occur in the setting of malignancy and other prothrombotic states. Prompt diagnosis with venous neuroimaging and early anticoagulation are central to management. Case Presentation: We report the case of a 33-year-old woman with metastatic hormone receptor-positive/HER2-negative breast cancer who developed intermittent right-sided tremor-like episodes shortly after her third cycle of sacituzumab govitecan. Magnetic resonance imaging demonstrated thrombosis involving the superior sagittal, right transverse, and right sigmoid sinuses, with extension into the visualized right internal jugular vein, and showed no intracranial metastases. She was treated initially with therapeutic enoxaparin, followed by apixaban, with early radiologic recanalization on follow-up MRV. Sacituzumab govitecan was continued after multidisciplinary discussion because a partial response of metastatic disease had been observed. Conclusion: This case highlights the need to consider CVT in patients with cancer who present with acute neurologic symptoms during systemic therapy and highlights diagnostic and therapeutic challenges in this context. We found no clearly indexed prior published case of CVT temporally associated with sacituzumab govitecan.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →